title: Dasatinib-letrozole gets split verdict.
abstract: Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer compared with letrozole alone, the clinical benefit was the same for both groups.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069439:Dasatinib; D005260:Female; D006801:Humans; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D000069439:Dasatinib; D000077289:Letrozole; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013844:Thiazoles; D014230:Triazoles